Recent Updates
Recently added Catalysts
CTMX

CytomX Therapeutics to Announce Second Quarter 2017 Financial Results and Provide Mid-Year Update

Key Takeaway: SOUTH SAN FRANCISCO, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will announce financial results for the second quarter ended June 30,

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
6.8%
average across 7 past catalysts
Cash runway
~54 mo
Minimal dilution risk
Lead asset
CX-2009
Phase 2 · Neoplasms

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will announce financial results for the second quarter ended June 30, 2017 and provide a mid-year update on August 7, 2017, after the NASDAQ market closing.
Conference Call/Webcast Information
Interested parties may access the live audio webcast of the teleconference at 5:00 p.m. ET through the Investor and News page of CytomX's website at http://ir.cytomx.com or by dialing 1-877-809-6037 and using the passcode 61956517.  A replay will be available on the CytomX website or by dialing 1-855-859-2056 and using the passcode 61956517.  The replay will be available from August 7, 2017, until August 14, 2017.
About CytomX Therapeutics
Last updated: Jul 27, 2017